Thank you for your interest in clinical research.
Below are links to our current studies that need volunteer participants. If you are interested in volunteering for a current study, or if you would like to be on our contact list for future studies, please contact ccfv@iwk.nshealth.ca or call 902-470-8141. Participants are compensated.
Phase 3 Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age
Participants needed: 16-40 years old, female
The purpose of this clinical trial is to evaluate the safety and effectiveness of an investigational vaccine against cytomegalovirus (CMV) infection in women who have not had prior CMV infection and evaluate its safety in women who test positive for CMV due to prior exposure.
Learn More About This StudyEffectiveness and safety of a Merck RSV prevention drug in infants and children at increased risk for RSV disease
Participants needed: Infants up to 1 year of age born earlier than 30 weeks gestation or with bronchopulmonary dysplasia or heart conditions present since birth
What is the purpose of the study? This study is testing MK-1654 in infants and… Read More»
Learn More About This StudyUnderstanding the effects of public health outbreak control policies and implementation on individuals and communities: A path to improving COVID-19 policy effectiveness
Participants needed:
Learn More About This StudyPhase 1/2 Study of 25-Valent Pneumococcal Conjugate Vaccine in Healthy PCV-Naïve Adults
Participants needed: Ages 18-40
Pneumococcal conjugate vaccines (PCVs) are lifesaving tools for children and cover 10, 13 or 20 varieties (or serotypes) of pneumococcus, but don’t yet cover some important serotypes that remain threats.
This early-stage Phase 1/2 clinical study will evaluate safety and immunogenicity (ability to produce an immune response) of a new PCV developed by Inventprise. The study vaccine is designed to cover 25 serotypes of pneumococcus posing greatest risk to children globally, but particularly in low- and middle-income regions where the pneumococcal disease burden is highest.
Learn More About This StudyPhase 1 Clinical Trial of mRNA-based monovalent influenza vaccine candidate
Participants needed: age 18-45
In this study, we will test a new mRNA vaccine against one type of influenza (also known as flu) virus. This study will look at how the body reacts to a Flu mRNA vaccine at different doses. We will give study participants different dose levels of this vaccine (this is called dose escalation). The good and bad effects of the mRNA vaccine will be studied.
Learn More About This StudyControlled Human Infection Model (pertussis)
Participants needed: Ages 18-40
CCfV is looking for healthy adult volunteers to participate in Canada’s first human challenge trial to better understand pertussis (whooping cough)
Learn More About This Study